Lexaria Bioscience

LEXX · Nasdaq · Canada

Share price · LEXX

$4.28-7.24 (-62.85%) 3M

close as of 2026-11-18 · 24h delayed · vol 13K (0.3x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when LEXX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Sep 2026-38.6%
  2. 9 Sep 2026-29.6%
  3. 8 Sep 2026-33.8%
  4. 13 Aug 2026+32.4%
  5. 4 Aug 2026+18.3%
  6. 3 Aug 2026-19.0%
  7. 30 Jul 2026-25.3%
  8. 17 Jul 2026+13.8%

    Nothing announced by LEXX that day or the session before.

  9. 8 Jul 2026+14.2%

    Nothing announced by LEXX that day or the session before.

  10. 18 Jun 2026-11.6%

Share of unusual movement by asset

For each asset, the share of LEXX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
DehydraTECH-CBD
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—34%
Sessions with no dated event—66%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 1
Oral peptide delivery platform · GLP-1 receptorCombination
Obesity
Preclinical / Unstaged
—Small molecule
Hypertension

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
November 2026 (1)
2026-08-31 Financial ReportEarnings report
Expected report date 2026-11-25 · Fiscal period ending 2026-08-31
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$0$1.0M$3.5M+ $0.1M short-term inv.$2.0M-$1.6M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1<$0.1M$0.5M$5.1M+ $0.1M short-term inv.$1.4M-$2.2M operating cash flowreport ↗
2025-Q4$0$0.7M$4.3M+ $0.1M short-term inv.$1.6M-$1.0M operating cash flowreport ↗
2025-Q2$0.2M$2.7M$4.6M+ <$0.1M short-term inv.$3.8M-$3.6M operating cash flowreport ↗
2025-Q1$0.2M$1.7M$6.5M+ $0.1M short-term inv.$2.7M-$1.5M operating cash flowreport ↗
2024-Q4$0.2M$1.9M$8.1M+ <$0.1M short-term inv.$2.7M-$2.7M operating cash flowreport ↗
2024-Q2$0.1M$0.6M$8.5M+ $0.1M short-term inv.$1.8M-$1.3M operating cash flowreport ↗
2024-Q1$0.1M$0.3M$4.7M+ $0.1M short-term inv.$0.7M-$0.6M operating cash flowreport ↗
2023-Q4$0.1M$0.6M$1.9M+ $0.1M short-term inv.$1.2M-$1.2M operating cash flowreport ↗
2023-Q2$0.1M$1.6M$3.2M+ $0.3M short-term inv.$2.4M-$1.8M operating cash flowreport ↗
2023-Q1<$0.1M$0.7M$3.3M+ $0.3M short-term inv.$1.3M-$1.2M operating cash flowreport ↗
2022-Q4$0.1M$0.8M$4.5M+ $0.3M short-term inv.$1.8M-$1.2M operating cash flowreport ↗
2022-Q2$0.1M$0.8M$7.0M+ $0.3M short-term inv.$2.4M-$1.3M operating cash flowreport ↗
2022-Q1<$0.1M$0.3M$8.4M+ $0.6M short-term inv.$1.4M-$1.3M operating cash flowreport ↗
2021-Q4<$0.1M$0.5M$9.7M+ $0.5M short-term inv.$2.0M-$1.2M operating cash flowreport ↗
2021-Q3——$11M+ $0.8M short-term inv.$1.2M-$1.1M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0.7M$8.2M$1.8M+ $0.1M short-term inv.$3.0M-$10M operating cash flowreport ↗

For fiscal 2025, Lexaria Bioscience reported revenue of $0.71M, up 54.3% YoY, with R&D spend of $8.24M, up 249.2% YoY. Cash and equivalents were $1.8M, and the company reported a net loss of $11.9M with a quarterly net burn of $11.9M.

During the year, Lexaria advanced its DehydraTECH drug-delivery platform across GLP-1/GIP and CBD programs, including human pilot studies of DehydraTECH-enhanced semaglutide, liraglutide, and tirzepatide, and reached last patient last visit in the chronic human study GLP-1-H24-4, with preliminary 8-week data showing reduced gastrointestinal adverse events versus Rybelsus. The company’s IND for DehydraTECH-CBD in hypertension remains active following an FDA Study May Proceed letter. It also expanded its patent portfolio, including diabetes, epilepsy, nicotine, and food and beverage patents, and maintained various licensing arrangements, with the Premier non-exclusive license expiring August 31, 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$0.5M$2.4M$6.5M+ $0.1M short-term inv.$1.4M-$5.0M operating cash flowreport ↗
2023-FY$0.2M$3.7M$1.4M+ $0.1M short-term inv.$1.7M-$5.9M operating cash flowreport ↗
2022-FY$0.3M$1.8M$5.8M+ $0.3M short-term inv.$1.8M-$4.9M operating cash flowreport ↗
2021-FY$0.7M$1.3M$11M+ $0.8M short-term inv.$1.1M-$4.0M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-03-17BUNKA CHRISTOPHER · directorGift100,000——Form 4
2025-07-30BUNKA CHRISTOPHER · directorOpen-market purchase11,900$0.91$11KForm 4
2025-07-29CHRISTOPHER RICHARD · director, Chief Executive OfficerOpen-market purchase15,000$0.91$14KForm 4
2025-07-29Carle Vanessa · SecretaryOpen-market purchase750$0.91$683Form 4
2025-07-29DOCHERTY JOHN MARTIN · director, President & CSOOpen-market purchase5,376$0.93$5KForm 4
2025-07-29McKechnie William Edward · directorOpen-market purchase5,000$0.91$5KForm 4
2025-07-29BUNKA CHRISTOPHER · directorOpen-market purchase15,600$0.92$14KForm 4
2025-05-15McKechnie William Edward · directorAward / grant (derivative)11,000——Form 4